Low Institute for Therapeutics

Low Institute for Therapeutics is a U.S.-based nonprofit drug discovery and translational therapeutics institute founded to advance discoveries originating from the Philip Low research program at Purdue University. The organization focuses on precision medicines designed to preferentially localize to diseased tissue, with programs spanning oncology, fibrosis, immunology, regenerative medicine, malaria, and sickle cell disease. LIFT positions itself as a bridge between academic discovery and for-profit clinical development, supporting preclinical work, early clinical studies, licensing, and partner-enabled commercialization. Its scientific heritage includes targeted drug delivery approaches that contributed to approved products such as Pluvicto, Locametz, and Cysview/Cytalux-related targeting work, while the institute reports multiple investigational programs in human studies.